HIV PrEP in teens: significant BMD changes, but renal function unaffected

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Teens who wish to take tenofovir/emtricitabine (Truvada) for HIV prevention should be followed carefully for bone mineral density (BMD) effects.

Why this matters                                                                             

  • Tenofovir (Viread) is known to worsen renal function and decrease bone density in adults, but little information is available on teens.

Key results

  • BMD declined significantly at 24 and 48 wk.
  • 2 participants sustained fractures during study period after trauma.
  • BMD declines were more pronounced among people with high levels of drug exposure, especially in total hip BMD.
  • BMD changes were correlated with drug concentrations at 12 wk, 24 wk, and 48 wk.
  • Estimated glomerular filtration rate and other markers of renal function did not change significantly during study.
  • Despite lack of changes to serum creatinine or eGFR, endocrine markers changed significantly by 8 wk in the high-adherence group.

Study design

  • Subanalysis of randomized controlled trial.
  • 101 young men who have sex with men without HIV enrolled in the ATN 117 study.
  • Funding: NIH.

Limitations

  • Sample size is modest, limiting the power of these findings.
  • Number of participants with significant drug concentrations was small.